– USA, MA – Eleven Biotherapeutics (NASDAQ:EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced the election of Paul Chaney, President and Chief Executive Officer of PanOptica, Inc., to the Company’s board of directors.
“Paul brings nearly 30 years of experience in the pharmaceutical industry, including 19 years of ophthalmic pharmaceutical development and commercial leadership experience, to Eleven,” said Abbie Celniker, Ph.D., President and Chief Executive Officer of Eleven. “Paul’s skills and experience in leading ophthalmology-focused biotechnology companies and pharmaceutical company business units will be valuable to Eleven as the Company advances its ophthalmic development programs.”
Paul Chaney is President and Chief Executive Officer of PanOptica, a private, venture-backed biopharmaceutical company focused on developing innovative ophthalmic therapeutics. Prior to co-founding PanOptica in 2009, Paul was Executive Vice President of OSI Pharmaceuticals, Inc. and President of (OSI) Eyetech, Inc., OSI Pharmaceuticals’ wholly-owned eyecare subsidiary. He joined Eyetech Pharmaceuticals, Inc. as Chief Operating Officer in 2003. Prior to joining Eyetech, Paul held a variety of senior management positions at Pharmacia Corporation, including Vice President of the Global Ophthalmology Business and Vice President of Global Pharmaceutical Ophthalmology. He began his career as a sales representative for The Upjohn Company in 1980. Paul earned a dual degree in Biological Sciences and English from the University of Delaware.
About Eleven Biotherapeutics
Eleven Biotherapeutics is a clinical-stage biopharmaceutical company with a proprietary protein engineering platform, called AMP-Rx, that it applies to the discovery and development of protein therapeutics to treat diseases of the eye. The Company’s therapeutic approach is based on the role of cytokines in diseases of the eye, the Company’s understanding of the structural biology of cytokines and the Company’s ability to rationally design and engineer proteins to modulate the effects of cytokines. Cytokines are cell signaling molecules found in the body that can have important inflammatory effects.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
